A Phase 3 Randomized 3-Part Study To Investigate The Efficacy And Safety Of Dupilumab In Adult And Adolescent Patients With Eosinophilic Esophagitis
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
Conditions: Eosinophilic Esophagitis
Age: Between 18 - 99 Years
Gender: Male or Female
Recruitment StatusEnrolling By Invitation
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com